At the same time, de novo proteins have also been applied to improve the efficacy of treatment methods in hematological disorders, such as designing the novel structures of chimeric antigen receptors, new inhibitors for treating chronic myeloid leukemia, and the novel type of interleukin-2. The gene discussed is IL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.